CXCR

CXCR4 blocker; triggers cell division failure in ovarian cancer, boosts taxol and docetaxel treatment effects, proven in mice.

PDE4-IN-1 is a PDE4 inhibitor characterized by high potency (IC50: 8.6 nM) and superior selectivity over other PDE subtypes. This compound inhibits the release of inflammatory cytokines and chemokines. Additionally, PDE4-IN-1 significantly restores the damaged cAMP-CREB signaling pathway, inhibits proliferation, and promotes differentiation to reverse psoriasis formation.

BVT173187 is a neutrophil formyl peptide receptors (FPR1) inhibitor.

ITIC-4F: a postfullerene IDTT electron acceptor for high-efficiency PSCs, relevant in binary, ternary, and tandem setups.

HuMax-IL8 (MDX 018) is a humanized anti-IL-8 monoclonal antibody for the study of metastatic or unresectable solid tumors.

CXCL-CXCR1/2-IN-1 is an ELR+CXCL-CXCR1/2 pathway inhibitor with anticancer activity and can be used in the study of cardiovascular disease.

T140, a Polyphemusin II-derived peptide, inhibits HIV-1 entry and blocks anti-CXCR4 antibody (12G5) binding.

KRH-3955 hydrochloride is an orally available CXCR4 blocker with IC50 of 0.61 nM and EC50 of 0.3-1.0 nM against X4 HIV-1.

CXCL8 (54-72) is a C-terminal peptide segment of the chemokine CXCL8. This peptide features a long, highly positively charged C-terminal region that interacts with the negative charges on glycosaminoglycans (GAG) to facilitate binding. CXCL8 (54-72) inhibits neutrophil adhesion and migration, as well as adhesion to endothelial cells. It is useful in studying the role of chemokines in inflammatory responses.

VB-85247 is a STING agonist that, by activating the STING pathway, induces the upregulation of inflammatory cytokines IFNα/β, TNFα, IL6, and CXCL10, as well as the maturation and activation of dendritic cells. It can lead to the regression of tumors within the bladder and is applicable in bladder cancer research.

Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic polypeptide targeting CXCR4, known for its significant anticancer properties. It inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and the development of lung metastasis, offering better serum stability and higher CXCR4 affinity (IC50=20 nM) compared to the lead compound. Peptide R54 works synergistically with anti-PD-1 therapy to exhibit antitumor effects in vivo, enhancing granzyme activity and reducing Foxp3 cell infiltration. It is useful for research in colon cancer, ovarian cancer, and melanoma.

vMIP-II (1-21) (NT21MP) TFA (TFA is a potent inhibitor of CXCR4. This compound interacts broadly with CC and CXC chemokine receptors. Furthermore, vMIP-II (1-21) TFA inhibits CXCR4 by competing for binding sites with 125I-SDF-1R, exhibiting an IC50 value of 190 nM.

Bam 12P is a Pro-Met-enkephalin precursor that is isolated from the bovine adrenal medulla.

CXCR7 modulator 1 is an effective and orally bioavailable peptoid hybrid CXCR7 modulator with Ki of 9 nM.

Vimnerixin (AZD4721) is an orally administered CXCR2 antagonist for inflammation studies.

RCP168 is a highly selective and potent CXCR4 receptor antagonist with an IC50 of 5 nM. It exhibits superior capacity to inhibit HIV-1 (Human Immunodeficiency Virus type 1) from entering host cells via the CXCR4 receptor compared to natural chemokines. RCP168 suppresses HIV-1 infection by blocking viral binding sites or inducing receptor internalization. It can be utilized in research to study interactions between the CXCR4 receptor and other chemokine receptors.

CXCR4 antagonist 1 is a potent inhibitor of the CXCR4 receptor, with notable anti-HIV activity.

CX4338 is a CXCL8-mediated chemotaxis inhibitor.

CXCR4 antagonist and ACKR3 (CXCR7) agonist (EC50 = 350 nM for CXCR7).

E70K, a CXCL8 C-terminal peptide, features a lysine (K) substitution for glutamic acid (E) at position 70 and has demonstrated the ability to attenuate